Table 2.

Lenalidomide Therapy Treatment–Related^* Thrombocytopenia or Neutropenia

Cytopenia on Therapy	MDS-003			MDS-002			P‡
	n	N†	%	n	N†	%
Thrombocytopenia	124	148	84	87	204	43	< .001
Baseline thrombocytopenia§	33	42	79	33	68	49	.003
No baseline thrombocytopenia	91	106	86	54	136	40	< .001
Neutropenia	61	148	41	92	210	43	.67
Baseline neutropenia‖	12	60	20	30	83	36	.042
No baseline neutropenia	49	88	56	62	127	49	.34

^*Treatment-related thrombocytopenia is defined as a ≥ 50% decrease in platelet count from baseline for MDS-002 and MDS-003. Treatment-related neutropenia is defined as a ≥ 50% decrease in absolute neutrophil count (ANC) from baseline for MDS-002 and a ≥ 75% decrease in ANC for MDS-003.

^†No. of patients with at least one nonmissing baseline and postbaseline neutrophil or platelet count measurement.

^‡Fisher's exact test, two-sided.

^§Baseline platelet count of < 150,000/μL.

^‖Baseline ANC of < 2000/μL.